Ebner N, von Haehling S
Klinik für Kardiologie und Pneumologie, Herzzentrum Göttingen, Georg-August-Universität, Robert-Koch-Str. 40, 37075, Göttingen, Deutschland.
Internist (Berl). 2018 May;59(5):439-444. doi: 10.1007/s00108-018-0408-3.
Alterations to the body composition, i.e. the makeup of skeletal muscle, fat and bone density, are frequent in heart insufficiency. Their prevalence and clinical consequences are often underestimated. Cachexia is recognized as a complex multifactorial syndrome in chronic diseases that leads to weight loss. This point constitutes the essential differential criterion from sarcopenia. Cachexia is defined as a non-edematous weight loss of more than 5% within 12 months or less. Cachexia means weight loss, while sarcopenia means loss of muscle mass without weight loss because the functional muscle can be replaced by adipocytes. Sarcopenia is defined as a skeletal muscle mass index (SMMI) of at least 2 standard deviations below the mean value of a healthy young reference group between 20 and 30 years of the same sex and ethnic background. At the same time the walking speed is reduced to 1 m/s or the distance covered in a 6-min walk is <400m. The determination of loss of muscle mass should be carried out by whole body scanning, ideally with dual-energy x‑ray absorptiometry. A reliable and simple method for measurement of performance capability is the short physical performance battery (SPPB) test. The treatment of sarcopenia and cardiac cachexia in patients with heart insufficiency is still a great challenge. Power and endurance training, nutritional supplementation and drug therapy are possible therapeutic approaches; however, the study situation is unsatisfactory.
心脏功能不全时,身体成分(即骨骼肌、脂肪和骨密度的构成)经常发生改变。其发生率和临床后果常常被低估。恶病质被认为是慢性疾病中导致体重减轻的一种复杂的多因素综合征。这一点构成了与肌肉减少症的主要鉴别标准。恶病质的定义为在12个月或更短时间内非水肿性体重减轻超过5%。恶病质意味着体重减轻,而肌肉减少症意味着肌肉量减少但体重未减轻,因为功能性肌肉可被脂肪细胞替代。肌肉减少症的定义为骨骼肌质量指数(SMMI)至少比同性别、同种族背景的20至30岁健康年轻参照组的平均值低2个标准差。同时,步行速度降至1米/秒或6分钟步行距离<400米。肌肉量减少的测定应通过全身扫描进行,理想情况下采用双能X线吸收法。一种可靠且简单的测量体能的方法是短身体性能电池(SPPB)测试。心力衰竭患者肌肉减少症和心脏恶病质的治疗仍然是一项巨大挑战。力量和耐力训练、营养补充和药物治疗都是可能的治疗方法;然而,研究现状并不令人满意。